• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anifrolumab: the new frontier in the treatment of genetic interferonopathies.

作者信息

Frémond Marie-Louise, David Clémence, Richez Christophe

机构信息

Department of Paediatric Hematology-Immunology and Rheumatology, Centre de Référence des Rhumatismes inflammatoires, maladies Auto-immunes et Interféronopathies Systémiques de l'Enfant RAISE, Necker-Enfants Malades Hospital, AP-HP, Paris, France

Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France.

出版信息

RMD Open. 2024 Sep 23;10(3):e004780. doi: 10.1136/rmdopen-2024-004780.

DOI:10.1136/rmdopen-2024-004780
PMID:39313304
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11418534/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/680f/11418534/c687f3c4005c/rmdopen-10-3-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/680f/11418534/c687f3c4005c/rmdopen-10-3-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/680f/11418534/c687f3c4005c/rmdopen-10-3-g001.jpg

相似文献

1
Anifrolumab: the new frontier in the treatment of genetic interferonopathies.阿尼鲁单抗：遗传性干扰素病治疗的新前沿。
RMD Open. 2024 Sep 23;10(3):e004780. doi: 10.1136/rmdopen-2024-004780.
2
Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies.I型干扰素病患者中 IFNAR1 阻断抗体（阿尼鲁单抗）的标准化干扰素特征和临床改善。
J Clin Immunol. 2024 Oct 23;45(1):31. doi: 10.1007/s10875-024-01826-2.
3
Anifrolumab to treat a monogenic interferonopathy.阿尼鲁单抗治疗单基因干扰素病。
J Allergy Clin Immunol Pract. 2024 May;12(5):1374-1376.e1. doi: 10.1016/j.jaip.2024.02.013. Epub 2024 Feb 17.
4
Anifrolumab: First Approval.阿尼鲁单抗：首次批准。
Drugs. 2021 Oct;81(15):1795-1802. doi: 10.1007/s40265-021-01604-z.
5
[Pharmacological actions of anifrolumab (Saphnelo) and clinical trial results as a treatment for systemic lupus erythematosus].阿尼鲁单抗（Saphnelo）的药理作用及作为系统性红斑狼疮治疗方法的临床试验结果
Nihon Yakurigaku Zasshi. 2022;157(4):271-279. doi: 10.1254/fpj.22026.
6
Anifrolumab in systemic lupus erythematosus.阿尼鲁单抗治疗系统性红斑狼疮。
Drugs Today (Barc). 2023 Feb;59(2):53-61. doi: 10.1358/dot.2023.59.2.3521876.
7
A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale.一项随机、平行分组、双盲、安慰剂对照的 3 期研究，旨在确定 I 型干扰素受体抗体阿尼鲁单抗在系统性硬化症中的有效性：DAISY 研究设计和原理。
Clin Exp Rheumatol. 2024 Aug;42(8):1635-1644. doi: 10.55563/clinexprheumatol/s8qcyu. Epub 2024 Aug 14.
8
Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus.阿尼鲁单抗：首个在欧盟获批的生物制剂，不限于疾病活动度高的患者，用于治疗中重度系统性红斑狼疮。
Expert Rev Clin Immunol. 2024 Jan-Jun;20(1):21-30. doi: 10.1080/1744666X.2023.2268284. Epub 2024 Jan 8.
9
Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.阿尼鲁单抗，一种针对 I 型干扰素受体亚单位 1 的单克隆抗体，用于治疗系统性红斑狼疮：临床试验概述。
Mod Rheumatol. 2021 Jan;31(1):1-12. doi: 10.1080/14397595.2020.1812201. Epub 2020 Sep 17.
10
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab.阿尼鲁单抗的临床药代动力学、药效学和免疫原性。
Clin Pharmacokinet. 2023 May;62(5):655-671. doi: 10.1007/s40262-023-01238-2. Epub 2023 May 6.

引用本文的文献

1
Anifrolumab Attenuates Follicular Helper T Cell Activation in Patients with Systemic Lupus Erythematosus.阿尼鲁单抗可减轻系统性红斑狼疮患者的滤泡辅助性T细胞活化。
Int J Mol Sci. 2025 Jul 31;26(15):7397. doi: 10.3390/ijms26157397.

本文引用的文献

1
Successful Treatment of Stimulator of Interferon Genes-Associated Vasculopathy of Infantile Onset SAVI Syndrome With Anifrolumab.用阿尼芬净成功治疗婴儿期起病的干扰素基因刺激因子相关血管病（SAVI）综合征
JAMA Dermatol. 2024 Aug 1;160(8):899-901. doi: 10.1001/jamadermatol.2024.2160.
2
Anifrolumab to treat a monogenic interferonopathy.阿尼鲁单抗治疗单基因干扰素病。
J Allergy Clin Immunol Pract. 2024 May;12(5):1374-1376.e1. doi: 10.1016/j.jaip.2024.02.013. Epub 2024 Feb 17.
3
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
I型干扰素抑制剂阿尼鲁单抗治疗活动性系统性红斑狼疮（TULIP-1）：一项随机、对照、3期试验
Lancet Rheumatol. 2019 Dec;1(4):e208-e219. doi: 10.1016/S2665-9913(19)30076-1. Epub 2019 Nov 11.
4
Anifrolumab for Adolescent Discoid Lupus Erythematosus.阿尼鲁单抗治疗青少年盘状红斑狼疮
JAMA Netw Open. 2023 Oct 2;6(10):e2338200. doi: 10.1001/jamanetworkopen.2023.38200.
5
Lung Transplantation under a Janus Kinase Inhibitor in Three Patients with SAVI Syndrome.三位 SAVI 综合征患者在使用 Janus 激酶抑制剂的情况下进行肺移植。
J Clin Immunol. 2023 Nov;43(8):2156-2164. doi: 10.1007/s10875-023-01595-4. Epub 2023 Oct 10.
6
Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus.阿尼鲁单抗：首个在欧盟获批的生物制剂，不限于疾病活动度高的患者，用于治疗中重度系统性红斑狼疮。
Expert Rev Clin Immunol. 2024 Jan-Jun;20(1):21-30. doi: 10.1080/1744666X.2023.2268284. Epub 2024 Jan 8.
7
JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study.JAK抑制在Aicardi-Goutières综合征中的应用：一项单中心多学科真实世界研究
J Clin Immunol. 2023 Aug;43(6):1436-1447. doi: 10.1007/s10875-023-01500-z. Epub 2023 May 12.
8
Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab?接受阿尼氟单抗治疗的系统性红斑狼疮患者发生重症新型冠状病毒肺炎的风险是否增加？
Lupus. 2023 Mar;32(3):453-455. doi: 10.1177/09612033231153536. Epub 2023 Jan 19.
9
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.一项评估阿尼鲁单抗在活跃系统性红斑狼疮患者中长期安全性和耐受性的随机、安慰剂对照 III 期扩展试验。
Arthritis Rheumatol. 2023 Feb;75(2):253-265. doi: 10.1002/art.42392. Epub 2022 Nov 11.
10
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.依洛尤单抗的疗效和安全性与 I 型干扰素基因特征和 SLE 患者的临床亚组有关：两项 III 期临床试验汇总数据的事后分析。
Ann Rheum Dis. 2022 Jul;81(7):951-961. doi: 10.1136/annrheumdis-2021-221425. Epub 2022 Mar 25.